William & Mary invites all lawyers in the William & Mary family to join us for a special reception & conversation on Health & Law at Biogen in Cambridge, Massachusetts. The Alumni Reception will take place on Monday, November 12 from 6:00 PM – 8:00 PM at one of the leading research facilities for Alzheimer’s.
Discussion: Research Advances & Legal Landscape for Neurological Diseases (Alzheimer’s disease, Parkinson’s disease, etc.)
Led by Law School Alumni Association Board Member:
Bart Newland J.D. ’84, Chief Intellectual Property Counsel at Biogen
Biogen has made a long-term commitment to furthering Alzheimer’s disease research and treatment. Their vision is to redefine Alzheimer’s disease through innovative medicines to improve the lives of patients and their caregivers. With an emphasis on early-stage disease, their research programs target several of the identified causes, amyloid and tau pathology – proteins believed to play a critical role in Alzheimer’s disease development. These programs range from preclinical experiments to Phase 3 clinical trials.
Their lead Alzheimer’s disease candidate, currently under development, is aducanumab, the first investigational drug to slow progression and reduce biological evidence of disease in an early clinical trial. Biogen hopes that aducanumab will be the first approved therapy to meaningfully change the course of Alzheimer’s disease and significantly improve the lives of Alzheimer’s patients and their families.
More information on Biogen can be found here: https://www.biogen.com/en_us/alzheimers-disease.html